Blood-Brain Barrier Penetration of Therapeutic Agents in Human

NCT04571996 | Completed Phase 1

• 1 other identifier: 3112012
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.

Conditions

CNS Disease

Keywords

Method; Blood Brain Barrier; Penetration; Therapeutics

Outcome Measures

Primary Outcomes (5)

• Cmax

  In plasma / CSF

  Daily PK samples during the first and last day of administration from day 1 to day 5-7

• Tmax

  In plasma / CSF

  Daily PK samples during the first and last day of administration from day 1 to day 5-7

• AUC

  In plasma / CSF

  Daily PK samples during the first and last day of administration from day 1 to day 5-7

• Cav

  In plasma / CSF

  Daily PK samples during the first and last day of administration from day 1 to day 5-7

• M/P ratio

  In plasma / CSF

  Daily PK samples during the first and last day of administration from day 1 to day 5-7

Study Arms (1)

ODM-104 and Panadol Zapp

EXPERIMENTAL

Drug: ODM-104; Drug: Paracetamol

Interventions

ODM-104 DRUG

Capsule

ODM-104 and Panadol Zapp

Paracetamol DRUG

Rapidly dissolving tablet

Also known as: Panadol Zapp

ODM-104 and Panadol Zapp

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent (IC) obtained before any study assessments are performed.
• Sufficient command of the Finnish language to be able to understand the subject information and to communicate with the study personnel.
• Males and females over 18 years of age.
• Body mass index (BMI) between 18-30 kg/m2.
• Idiopathic normal pressure hydrocephalus.
• Shunt surgery with cerebroventricular catheter placed at least 3 months earlier.
• Good general health, based on medical history, physical examination and laboratory assessments.
• Adequate mental status to give informed consent as assessed by the investigator and using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery.
• Female participants of child-bearing potential and male participants with female partners of child-bearing potential must adhere to a highly effective form of contraception (listed in Section 4.6) from the first study treatment administration until 1 month after the EoS visit.

You may not qualify if:

• Predicted poor compliance with study procedures, restrictions and requirements.
• Vulnerable subjects (i.e. persons under any administrative or legal supervision).
• Veins unsuitable for repeated venipuncture or cannulation
• Evidence of other current clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolicendocrine, neurological, urogenital or psychiatric disease than iNPH, as judged by the investigator.
• Type 1 diabetes mellitus.
• Diagnosis of cancer for which the subject is currently being treated, or for which there is evidence of active disease. Subjects with local prostate cancer or local dermatological tumours, such as basal or squamous cell carcinoma, may be included.
• Susceptibility to severe allergic reactions, e.g. history of anaphylactic shock due to any reason.
• Use of medications impacting the metabolism of dopamine, such as other COMT inhibitors (e.g. entacapone), levodopa and monoamine oxidase (MAO) inhibitors (e.g. rasagiline, selegiline), within 4 weeks before the first study drug administration.
• Any clinically significant abnormalities in screening laboratory test results, vital signs or physical examination findings that might influence the results of the study or cause a health risk for the subject if he/she takes part in the study.
• Any clinically significant 12-lead ECG abnormality, such as QTcF \> 450 ms, after 10 min rest in supine position at the screening visit.
• Heart rate (HR) \< 50 bpm or \> 90 bpm, systolic blood pressure (BP) \< 90 mmHg or \> 160 mmHg, or diastolic BP \< 50 mmHg or \> 100 mmHg in supine or seated position after 10 min rest at the screening visit.
• Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).
• History of alcohol or drug abuse within the last 5 years, or current regular use of illicit drugs or excessive use of alcohol (regular alcohol drinking of more than 24 units/week for males or 14 units/week for females), or positive breath test for alcohol or positive urine test for drugs of abuse at screening or prior to the first IMP administration.
• Inability to refrain from consuming caffeine-containing beverages during the stay in the unit.
• Current use of nicotine-containing products, more than 5 cigarettes or equivalent/day, or inability to refrain from using nicotine-containing products during the stay at the study centre.

Sponsors & Collaborators

• Orion Corporation, Orion Pharma: lead

Study Sites (1)

CRST Turku

Turku, Finland

Location

MeSH Terms

Conditions

Central Nervous System Diseases

Interventions

Acetaminophen

Condition Hierarchy (Ancestors)

Nervous System Diseases

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Orion Pharma Clinical study director

  Orion Corporation, Orion Pharma

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 25, 2020
• First Posted: October 1, 2020
• Study Start: October 29, 2020
• Primary Completion: February 23, 2021
• Study Completion: February 23, 2021
• Last Updated: April 13, 2021

Record last verified: 2021-04

Locations

FI (1)